Part II: Functional delivery of a neurotherapeutic gene to neural stem cells using minicircle DNA and nanoparticles: Translational advantages for regenerative neurology

Journal of Controlled Release

Volumn 238, Issue , 2016, Pages 300-310

  Fernandes, Alinda R ^a   Chari, Divya M ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

BDNF; Genetic engineering; Magnetofection; Minicircle; Neural stem cells

Indexed keywords

CELL ENGINEERING; CELLS; CYTOLOGY; DISEASE CONTROL; ENZYME INHIBITION; GENE THERAPY; GENE TRANSFER; GENES; GENETIC ENGINEERING; MEDICAL APPLICATIONS; NANOMAGNETICS; NANOPARTICLES; NEUROLOGY;

ACCELERATED MATURATION; BDNF; BRAIN-DERIVED NEUROTROPHIC FACTORS; MAGNETIC NANO-PARTICLES; MAGNETOFECTION; MINICIRCLE; NEURAL STEM CELL; REGENERATIVE EFFECTS;

STEM CELLS;

BRAIN DERIVED NEUROTROPHIC FACTOR; MINICIRCLE DNA; NANOPARTICLE; DNA;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA VECTOR; FEASIBILITY STUDY; GENETIC ENGINEERING; IN VITRO STUDY; MAGNETOFECTION; MOUSE; NERVE CELL; NERVE FIBER GROWTH; NEURAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; CYTOLOGY; GENETIC TRANSFECTION; GENETICS; HUMAN; MAGNETIC FIELD; METABOLISM; NERVOUS SYSTEM DEVELOPMENT; PLASMID; PROCEDURES; UPREGULATION;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DIFFERENTIATION; DNA; GENETIC ENGINEERING; HUMANS; MAGNETIC FIELDS; MICE; NANOPARTICLES; NEURAL STEM CELLS; NEUROGENESIS; PLASMIDS; TRANSFECTION; UP-REGULATION;

EID: 84979609017     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.06.039     Document Type: Article

References (63)

1. [1] Liang, W., Han, Q., Jin, W., Xiao, Z., Huang, J., Ni, H., et al. The promotion of neurological recovery in the rat spinal cord crushed injury model by collagen-binding BDNF. Biomaterials 31 (2010), 8634–8641, 10.1016/j.biomaterials.2010.07.084.
2. [2] Kromer, L.F., Nerve growth factor treatment after brain injury prevents neuronal death. Science 235 (1987), 214–216.
3. [3] Feng, Y., Rhodes, P.G., Bhatt, A.J., Neuroprotective effects of vascular endothelial growth factor following hypoxic ischemic brain injury in neonatal rats. Pediatr. Res. 64 (2008), 370–374, 10.1203/PDR.0b013e318180ebe6.
4. [4] Lindvall, O., Kokaia, Z., Stem cells in human neurodegenerative disorders — time for clinical translation?. J. Clin. Invest., 120, 2010, 29, 10.1172/JCI40543.patients.
5. [5] Kim, S.U., Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathol. Off. J. Jpn. Soc. Neuropathol. 24 (2004), 159–171, 10.1111/j.1440-1789.2004.00552.x.
6. [6] Nagahara, A.H., Merrill, D.A., Coppola, G., Tsukada, S., Schroeder, B.E., Shaked, G.M., et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15 (2009), 331–337, 10.1038/nm.1912.
7. [7] Fumagalli, F., Racagni, G., Riva, M.A., The expanding role of BDNF: a therapeutic target for Alzheimer's disease?. Pharmacogenomics J. 6 (2006), 8–15, 10.1038/sj.tpj.6500337.
8. [8] Schäbitz, W.R., Sommer, C., Zoder, W., Kiessling, M., Schwaninger, M., Schwab, S., Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke J. Cereb. Circ. 31 (2000), 2212–2217, 10.1161/01.STR.31.9.2212.
9. [9] Ochs, G., Penn, R.D., York, M., Giess, R., Beck, M., Tonn, J., et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 1, 2000, 201–206, 10.1080/14660820050515197.
10. [10] Lee, H.J., Lim, I.J., Lee, M.C., Kim, S.U., Human neural stem cells genetically modified to overexpress brain-derived neurotrophic factor promote functional recovery and neuroprotection in a mouse stroke model. J. Neurosci. Res. 88 (2010), 3282–3294, 10.1002/jnr.22474.
11. [11] Falk, A., Holmström, N., Carlén, M., Cassidy, R., Lundberg, C., Frisén, J., Gene delivery to adult neural stem cells. Exp. Cell Res. 279 (2002), 34–39.
12. [12] Wu, P., Ye, Y., Svendsen, C.N., Transduction of human neural progenitor cells using recombinant adeno-associated viral vectors. Gene Ther. 9 (2002), 245–255, 10.1038/sj.gt.3301646.
13. [13] Mintzer, M.A., Simanek, E.E., Nonviral vectors for gene delivery. Chem. Rev. 109 (2009), 259–302.
14. [14] Elsabahy, M., Nazarali, A., Foldvari, M., Non-viral nucleic acid delivery: key challenges and future directions. Curr. Drug Deliv. 8 (2011), 235–244.
15. [15] Adams, C.F., Pickard, M.R., Chari, D.M., Magnetic nanoparticle mediated transfection of neural stem cell suspension cultures is enhanced by applied oscillating magnetic fields. Nanomed. Nanotechnol. Biol. Med. 9 (2013), 737–741, 10.1016/j.nano.2013.05.014.
16. [16] Jenkins, S.I., Pickard, M.R., Furness, D.N., Yiu, H.H., Chari, D.M., Differences in magnetic particle uptake by CNS neuroglial subclasses: implications for neural tissue engineering. Nanomedicine (Lond.), 2012, 10.2217/nnm.12.145 (Epub ahead of print).
17. [17] Fernandes, A.R., Chari, D.M., A multicellular neuro-mimetic model to study nanoparticle Uptake in Cells of the Central Nervous System. Integr. Biol. (Camb). 6 (2014), 855–861, 10.1039/c4ib00085d.
18. 4-PEI-RITC magnetic nanoparticles with imaging and gene transfer capability: development of a tool for neural cell transplantation therapies. Pharm. Res. 29 (2012), 1328–1343, 10.1007/s11095-011-0632-1.
19. [19] Pickard, M.R., Barraud, P., Chari, D.M., The transfection of multipotent neural precursor/stem cell transplant populations with magnetic nanoparticles. Biomaterials 32 (2011), 2274–2284, 10.1016/j.biomaterials.2010.12.007.
20. [20] Jenkins, S.I., Pickard, M.R., Granger, N., Chari, D.M., Magnetic nanoparticle-mediated gene transfer to oligodendrocyte precursor cell transplant populations is enhanced by magnetofection strategies. ACS Nano 5 (2011), 6527–6538, 10.1021/nn2018717.
21. [21] Tickle, J.A., Jenkins, S.I., Pickard, M.R., Chari, D.M., Influence of amplitude of oscillating magnetic fields on magnetic nanoparticle-mediated gene transfer to astrocytes. Nano LIFE, 5, 2014, 1450006, 10.1142/S1793984414500068.
22. [22] Pickard, M., Chari, D., Enhancement of magnetic nanoparticle-mediated gene transfer to astrocytes by “magnetofection”: effects of static and oscillating fields. Nanomedicine (Lond.) 5 (2010), 217–232, 10.2217/nnm.09.109.
23. [23] Pickard, M., Adams, C., Barraud, P., Chari, D., Using magnetic nanoparticles for gene transfer to neural stem cells: stem cell propagation method influences outcomes. J. Funct. Biomater. 6 (2015), 259–276, 10.3390/jfb6020259.
24. [24] Xu, X., Capito, R.M., Spector, M., Plasmid size influences chitosan nanoparticle mediated gene transfer to chondrocytes. J. Biomed. Mater. Res. A 84 (2008), 1038–1048, 10.1002/jbm.a.31479.
25. [25] Yin, W., Xiang, P., Li, Q., Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Anal. Biochem. 346 (2005), 289–294, 10.1016/j.ab.2005.08.029.
26. [26] Kreiss, P., Cameron, B., Rangara, R., Mailhe, P., Aguerre-Charriol, O., Airiau, M., et al. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res. 27 (1999), 3792–3798 (doi:gkc575 [pii).
27. [27] Sum, C.H., Wettig, S., Slavcev, R.A., Impact of DNA vector topology on non-viral gene therapeutic safety and efficacy. Curr. Gene Ther. 14 (2014), 309–329, 10.2174/1566523214666140612154929.
28. [28] Sicard, F., Sapet, C., Laurent, N., Bertosio, E., Bertuzzi, M., Zelphati, O., Magneetofection of minicircle DNA vectors. Minicircle and Miniplasmid DNA Vectors: The Future of Nonviral and Viral Gene Transfer, 2013, 165–176, 10.1002/9783527670420.ch9.
29. [29] Gracey Maniar, L.E., Maniar, J.M., Chen, Z.-Y., Lu, J., Fire, A.Z., Kay, M.a., Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol. Ther. J. Am. Soc. Gene Ther. 21 (2013), 131–138, 10.1038/mt.2012.244.
30. [30] Mayrhofer, P., Schleef, M., Jechlinger, W., Use of minicircle plasmids for gene therapy. Methods Mol. Biol. 542 (2009), 87–104, 10.1007/978-1-59745-561-9_4.
31. [31] Chen, Z.Y., He, C.Y., Ehrhardt, A., Kay, M.A., Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol. Ther. 8 (2003), 495–500, 10.1016/S1525-0016(03)00168-0.
32. [32] Darquet, A.M., Cameron, B., Wils, P., Scherman, D., Crouzet, J., A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 4 (1997), 1341–1349, 10.1038/sj.gt.3300540.
33. [33] EMA, CPMP/BWP/3088/99 — Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products, Guideline. 2001, 33 doi:CPMP/BWP/3088/99.
34. [34] Qin, J.Y., Zhang, L., Clift, K.L., Hulur, I., Xiang, A.P., Ren, B.Z., et al. Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS ONE, 5, 2010, 10.1371/journal.pone.0010611.
35. [35] Hong, S., Hwang, D.Y., Yoon, S., Isacson, O., Ramezani, A., Hawley, R.G., et al. Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol. Ther. 15 (2007), 1630–1639 E:\AlexGlassman\Artikel\Neuronal Development\Hong-S_MolTher_2007.pdf\nhttp://dx. doi.org/10.1038/sj.mt.6300251.
36. [36] Norrman, K., Fischer, Y., Bonnamy, B., Sand, F.W., Ravassard, P., Semb, H., Quantitative comparison of constitutive promoters in human ES cells. PLoS ONE, 5, 2010, 10.1371/journal.pone.0012413.
37. [37] Greenberg, M.E., Xu, B., Lu, B., Hempstead, B.L., New insights in the biology of BDNF synthesis and release: implications in CNS function. J. Neurosci. Off. J. Soc. Neurosci. 29 (2009), 12764–12767, 10.1523/JNEUROSCI.3566-09.2009.
38. [38] Pickard, M.R., Barraud, P., Chari, D.M., The transfection of multipotent neural precursor/stem cell transplant populations with magnetic nanoparticles. Biomaterials 32 (2011), 2274–2284, 10.1016/j.biomaterials.2010.12.007.
39. [39] Chen, S.-Q., Cai, Q., Shen, Y.-Y., Cai, X.-Y., Lei, H.-Y., Combined use of NGF/BDNF/bFGF promotes proliferation and differentiation of neural stem cells in vitro. Int. J. Dev. Neurosci. Off. J. Int. Soc. Dev. Neurosci. 38 (2014), 74–78, 10.1016/j.ijdevneu.2014.08.002.
40. [40] Islam, O., Loo, T.X., Heese, K., Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways. Curr. Neurovasc. Res. 6 (2009), 42–53, 10.2174/156720209787466028.
41. [41] Maurer, M.H., Thomas, C., Burgers, H.F., Kuschinsky, W., Transplantation of adult neural progenitor cells transfected with vascular endothelial growth factor rescues grafted cells in the rat brain. Int. J. Biol. Sci. 4 (2008), 1–7 ( http://www.ncbi.nlm.nih.gov/pubmed/18167530).
42. [42] Mokry, J., Karbanova, J., Filip, S., Differentiation potential of murine neural stem cells in vitro and after transplantation. Transplant. Proc. 37 (2005), 268–272 doi:S0041–1345(04)01691–4 [pii]\r10.1016/j.transproceed.2004.12.233.
43. [43] Schinstine, M., Iacovitti, L., 5-Azacytidine and BDNF enhance the maturation of neurons derived from EGF-generated neural stem cells. Exp. Neurol. 144 (1997), 315–325, 10.1006/exnr.1996.6370.
44. [44] Choi, K.-C., Yoo, D.-S., Cho, K.-S., Huh, P.-W., Kim, D.-S., Park, C.-K., Effect of single growth factor and growth factor combinations on differentiation of neural stem cells. J. Korean Neurosurg. Soc. 44 (2008), 375–381, 10.3340/jkns.2008.44.6.375.
45. [45] Ahmed, S., Reynolds, B.A., Weiss, S., BDNF enhances the differentiation but not the survival of CNS stem cell-derived neuronal precursors. J. Neurosci. Off. J. Soc. Neurosci. 15 (1995), 5765–5778.
46. [46] Tong, L., Perez-Polo, R., Brain-derived neurotrophic factor (BDNF) protects cultured rat cerebellar granule neurons against glucose deprivation-induced apoptosis. J. Neural Transm. 105 (1998), 905–914 Vienna, Austria : 1996. ( http://www.ncbi.nlm.nih.gov/pubmed/9869325).
47. [47] Lindholm, D., Dechant, G., Heisenberg, C.P., Thoenen, H., Brain-derived neurotrophic factor is a survival factor for cultured rat cerebellar granule neurons and protects them against glutamate-induced neurotoxicity. Eur. J. Neurosci. 5 (1993), 1455–1464 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7904521.
48. [48] Kubo, T., Nonomura, T., Enokido, Y., Hatanaka, H., Brain-derived neurotrophic factor (BDNF) can prevent apoptosis of rat cerebellar granule neurons in culture. Brain Res. Dev. Brain Res. 85 (1995), 249–258.
49. [49] Adams, C.F., Pickard, M.R., Chari, D.M., Magnetic nanoparticle mediated transfection of neural stem cell suspension cultures is enhanced by applied oscillating magnetic fields. Nanomed. Nanotechnol. Biol. Med. 9 (2013), 737–741, 10.1016/j.nano.2013.05.014.
50. [50] Pickard, M.R., Barraud, P., Chari, D.M., The transfection of multipotent neural precursor/stem cell transplant populations with magnetic nanoparticles. Biomaterials 32 (2011), 2274–2284, 10.1016/j.biomaterials.2010.12.007.
51. [51] Adams, C.F., Rai, A., Sneddon, G., Yiu, H.H.P., Polyak, B., Chari, D.M., Increasing magnetite contents of polymeric magnetic particles dramatically improves labeling of neural stem cell transplant populations. Nanomed. Nanotechnol. Biol. Med., 2014, 10.1016/j.nano.2014.07.001.
52. [52] Gu, S.H., Xu, W.D., Xu, L., Li, X.K., Ochiya, T., Wang, Y., et al. Regenerated host axons form synapses with neurons derived from neural stem cells transplanted into peripheral nerves. J. Int. Med. Res. 38 (2010), 1721–1729.
53. [53] Liu, D., Bi, Y., Liu, Z., Liu, H., Li, Z., The expression of vesicular glutamate transporter 3 and vesicular monoamine transporter 2 induced by brain-derived neurotrophic factor in dorsal root ganglion neurons in vitro. Brain Res. Bull. 100 (2014), 93–106, 10.1016/j.brainresbull.2013.11.007.
54. [54] Blurton-Jones, M., Kitazawa, M., Martinez-Coria, H., Castello, N.A., Müller, F.-J., Loring, J.F., et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 13594–13599, 10.1073/pnas.0901402106.
55. [55] Wang, Z.H., Ji, Y., Shan, W., Zeng, B., Raksadawan, N., Pastores, G.M., et al. Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson's disease. Neuroscience 113 (2002), 629–640, 10.1016/S0306-4522(02)00204-X.
56. [56] Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O., Hashimoto, N., Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 37 (1995), 733–739 (discussion 739–41. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8559303).
57. [57] Géral, C., Angelova, A., Lesieur, S., From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF). Pharmaceutics 5 (2013), 127–167, 10.3390/pharmaceutics5010127.
58. [58] Nagahara, A.H., Tuszynski, M.H., Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. 10 (2011), 209–219, 10.1038/nrd3366.
59. [59] Schwieger, J., Warnecke, A., Lenarz, T., Esser, K.H., Scheper, V., Forsythe, J., Neuronal survival, morphology and outgrowth of spiral ganglion neurons using a defined growth factor combination. PLoS ONE, 10, 2015, 10.1371/journal.pone.0133680.
60. [60] Mayrhofer, P., Blaesen, M., Schleef, M., Jechlinger, W., Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J. Gene Med. 10 (2008), 1253–1269, 10.1002/jgm.1243.
61. [61] Teoh, W.Y., Amal, R., Mädler, L., Flame spray pyrolysis: an enabling technology for nanoparticles design and fabrication. Nanoscale 2 (2010), 1324–1347, 10.1039/c0nr00017e.
62. [62] Yanamandra, K., Jiang, H., Mahan, T.E., Maloney, S.E., Wozniak, D.F., Diamond, M.I., et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann. Clin. Transl. Neurol. 2 (2015), 278–288, 10.1002/acn3.176.
63. [63] Pardridge, W.M., Biologic TNFalpha-inhibitors that cross the human blood-brain barrier. Bioeng. Bugs. 1 (2010), 231–234, 10.4161/bbug.1.4.12105.